Today, Illumina Inc Inc’s (NASDAQ: ILMN) stock fell $0.17, accounting for a 0.04% decrease. Illumina opened at $436.69 before trading between $436.69 and $431.38 throughout Wednesday’s session. The activity saw Illumina’s market cap fall to $63,754,353,000 on 1,023,602 shares -above their 30-day average of 822,092.
About Illumina Inc
Illumina is improving human health by unlocking the power of the genome. Its focus on innovation has established it as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. The Company products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.
Visit Illumina Inc’s profile for more information.
The Daily Fix
Breakthrough Energy, a non-profit launched by billionaire philanthropist and Microsoft (NASDAQ: MSFT) co-founder Bill Gates in 2016, has raised a warchest from seven leading global corporations to further the organization’s mission of reaching a net-zero emissions society by 2050.
JPMorgan is following Goldman Sachs into a crowded UK market.
About The Nasdaq Stock Market
The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world’s leading exchange for options volume and is home to the five largest US companies – Apple, Microsoft, Amazon, Alphabet and Facebook.
To get more information on Illumina Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Illumina Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.
Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.
The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: www.equities.com/disclaimer
Read more here: Source link